Digestion resistant dextrin (DRD), also known as resistant maltodextrin, is a type of soluble dietary fiber that is not digested in the small intestine and reaches the colon mostly intact. Its use to support or treat metabolic syndrome is primarily grounded in scientific research rather than tradition. Multiple clinical trials and meta-analyses have investigated the effects of resistant dextrin on markers of metabolic syndrome, including blood glucose regulation, insulin sensitivity, lipid profiles, and body weight management.

Evidence suggests that DRD may help improve glycemic control by slowing glucose absorption and reducing postprandial blood sugar spikes. Some studies report modest reductions in fasting blood glucose and HbA1c levels in individuals with impaired glucose tolerance or type 2 diabetes. DRD has also been associated with improvements in certain lipid parameters, such as decreased total and LDL cholesterol, and may support modest weight loss or reductions in visceral fat when used as part of a calorie-controlled diet. These benefits are thought to arise from its ability to modulate gut microbiota, increase short-chain fatty acid production, and promote satiety.

While results are generally positive, the magnitude of effect is moderate, and not all studies show consistent benefits across all markers of metabolic syndrome. Thus, the overall evidence rating is a 3 out of 5, reflecting moderate scientific support but not definitive proof. DRD is considered a safe and well-tolerated adjunct to dietary interventions for metabolic syndrome but should not replace established medical therapies.